The role of intraluminal radiotherapy and concurrent 5‐fluorouracil infusion in the management of carcinoma esophagus: A pilot study

Dinshaw, Ketayun A.; Sharma, Vinay; Pendse, A M; Telang, Champat S.; Vege, Shanti Swaroop; Malliat, Mohandas K.; Deshpande, Ramakant; Desai, P. B.

doi:10.1002/jso.2930470304

Cited by 18 publications

(7 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As published earlier, 15 the addition of 5-¯uorouracil with intraluminal brachytherapy suggested improved results. It was decided to continue the 5-¯uorouracil for both groups using 500 mg/m 2 i.v.…”

Section: Concurrent Chemotherapy With Intraluminal Brachytherapysupporting

confidence: 59%

See 1 more Smart Citation

Late esophageal toxicity using a combination of external beam radiation, intraluminal brachytherapy and 5-fluorouracil infusion in carcinoma of the esophagus

Sharma¹,

Agarwal²,

Dinshaw³

et al. 2000

Dis Esophagus

View full text Add to dashboard Cite

One hundred patients with potentially curable squamous cell carcinoma of the esophagus were treated using a combination of external beam radiation, medium-dose intraluminal brachytherapy (ILBT), and 5-fluorouracil infusion (as a radiosensitizer) from January 1990 to December 1993. The main objective was to determine late toxicity and optimization of the dose of intraluminal radiation. All patients had external radiation of 50 Gy over 5 1/2 weeks, followed by ILBT of 20 Gy for 50 patients (group 1) and 15 Gy for a subsequent 50 patients (group 2), using a dose rate of 315-330 cGy/h with the prescription at 1 cm off axis. The 5-fluorouracil infusion was 500 mg/m2 administered 12 h prior to ILBT. The treatment-related complications among groups 1 and 2 were strictures 24% vs. 8% (p = 0.029), ulceration 30% vs. 28% (p = 0.8), and tracheoesophageal fistulae 12% for both groups. The overall survival for groups 1 and 2 was 8% and 23% at 5 years. The development of life-threatening complications is a major concern and extreme caution is urged before selecting patients for a combination of ILBT and 5-fluorouracil treatment.

show abstract

Section: Concurrent Chemotherapy With Intraluminal Brachytherapysupporting

confidence: 59%

“…At our centre, intraluminal brachytherapy for carcinoma of the esophagus has been used since 1988. The results of a randomized study using ILRT alone vs. ILRT + 5-¯uorouracil following external beam radiation for radical treatment, 15,16 as well as in palliation for advanced/recurrent disease, 17 have been encouraging.…”

Section: Introductionmentioning

confidence: 99%

Late esophageal toxicity using a combination of external beam radiation, intraluminal brachytherapy and 5-fluorouracil infusion in carcinoma of the esophagus

Sharma¹,

Agarwal²,

Dinshaw³

et al. 2000

Dis Esophagus

View full text Add to dashboard Cite

show abstract

“…Various authors have reported improved swallowing ranging from 56% to 96% for a variable period of time using the combination of intraluminal radiation at either a low or high dose rate and external beam radiation therapy 10 , 15 , 34 , 38 , 44 , 47 , 48 . In the present series, 43% of patients showed an improvement in swallowing and another 47% were able to maintain pretreatment swallowing.…”

Section: Discussionmentioning

confidence: 99%

“…As published earlier, 15 the addition of 5‐fluorouracil with intraluminal brachytherapy suggested improved results. It was decided to continue the 5‐fluorouracil for both groups using 500 mg/m 2 i.v.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Late esophageal toxicity using a combination of external beam radiation, intraluminal brachytherapy and 5-fluorouracil infusion in carcinoma of the esophagus

Sharma

Agarwal

Dinshaw

et al. 2008

Diseases of the Esophagus

View full text Add to dashboard Cite

One hundred patients with potentially curable squamous cell carcinoma of the esophagus were treated using a combination of external beam radiation, medium-dose intraluminal brachytherapy (ILBT), and 5-¯uorouracil infusion (as a radiosensitizer) from January 1990 to December 1993. The main objective was to determine late toxicity and optimization of the dose of intraluminal radiation. All patients had external radiation of 50 Gy over 5 weeks, followed by ILBT of 20 Gy for 50 patients (group 1) and 15 Gy for a subsequent 50 patients (group 2), using a dose rate of 315±330 cGy/h with the prescription at 1 cm o axis. The 5-¯uorouracil infusion was 500 mg/m 2 administered 12 h prior to ILBT. The treatment-related complications among groups 1 and 2 were strictures 24% vs. 8% (p=0.029), ulceration 30% vs. 28% (p=0.8), and tracheoesophageal ®stulae 12% for both groups. The overall survival for groups 1 and 2 was 8% and 23% at 5 years. The development of life-threatening complications is a major concern and extreme caution is urged before selecting patients for a combination of ILBT and 5-¯uorouracil treatment.

show abstract

Brachytherapy and continuous infusion 5-fluorouracil for the treatment of locally advanced, lymph node negative, prostate cancer: A phase I trial

See¹,

Dreicer²,

Wheeler³

et al. 1996

Cancer

View full text Add to dashboard Cite

The role of intraluminal radiotherapy and concurrent 5‐fluorouracil infusion in the management of carcinoma esophagus: A pilot study

Cited by 18 publications

References 26 publications

Late esophageal toxicity using a combination of external beam radiation, intraluminal brachytherapy and 5-fluorouracil infusion in carcinoma of the esophagus

Late esophageal toxicity using a combination of external beam radiation, intraluminal brachytherapy and 5-fluorouracil infusion in carcinoma of the esophagus

Late esophageal toxicity using a combination of external beam radiation, intraluminal brachytherapy and 5-fluorouracil infusion in carcinoma of the esophagus

Brachytherapy and continuous infusion 5-fluorouracil for the treatment of locally advanced, lymph node negative, prostate cancer: A phase I trial

Contact Info

Product

Resources

About